Immune checkpoint blockade therapy has become a major weapon in fighting cancer.
Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such …

T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM
family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and …

Tumor development and metastasis are facilitated by the complex interactions between
cancer cells and their microenvironment, which comprises stromal cells and extracellular …

The blockade of immune checkpoint receptors has made great strides in the treatment of
major cancers, including melanoma, Hodgkin's lymphoma, renal, and lung cancer. However …

The development of immunotherapies over the past decade has resulted in a paradigm shift
in the treatment of cancer. However, the majority of patients do not benefit from …

Immune checkpoint proteins (ICP) are currently one of the most novel and promising areas
of immune-oncology research. This novel way of targeting tumor cells has shown favorable …

Immunotherapy, with an increasing number of therapeutic dimensions, is becoming an
important mode of treatment for cancer patients. The inhibition of immune checkpoints …

Co-inhibitory receptors, such as CTLA-4 and PD-1, have an important role in regulating T
cell responses and have proven to be effective targets in the setting of chronic diseases …

Immunotherapy is being increasingly recognized as a key therapeutic modality to treat
cancer and represents one of the most exciting treatments for the disease. Fighting cancer …

T cell responses must be balanced to ensure adequate protection against malignant
transformation and an array of pathogens while also limiting damage to healthy cells and …